Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience

Ferlay J. , Shin H.R. , Bray F. , Forman D. , Mathers C. , Parkin D.M. : Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893–2917, 2010.

Powell J. , McConkey C.C. : Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer, 62: 440–443, 1990.

Wagner A.D. , Grothe W. , Haerting J. , Kleber G. , Grothey A. , Fleig W.E. : Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24: 2903–2909, 2006.

Van Cutsem E. , Moiseyenko V.M. , Tjulandin S. , Majlis A. , Constenla M. , Boni C. , Rodrigues A. , Fodor M. , Chao Y. , Voznyi E. , Risse M.L. , Ajani J.A. ; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24: 4991–4997, 2006.

Cunningham D. , Starling N. , Rao S. , Iveson T. , Nicolson M. , Coxon F. , Middleton G. , Daniel F. , Oates J. , Norman A.R. ; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358: 36–46, 2008.

Gravalos C. , Jimeno A. : HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19: 1523–1529, 2008.

Hofmann M. , Stoss O. , Shi D. , Büttner R. , van de Vijver M. , Kim W. , Ochiai A. , Rüschoff J. , Henkel T. : Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52: 797–805, 2008.

Tanner M. , Hollmén M. , Junttila T.T. , Kapanen A.I. , Tommola S. , Soini Y. , Helin H. , Salo J. , Joensuu H. , Sihvo E. , Elenius K. , Isola J. : Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 16: 273–278, 2005.

Kunz P.L. , Mojtahed A. , Fisher G.A. , Ford J.M. , Chang D.T. , Balise R.R. , Bangs C.D. , Cherry A.M. , Pai R.K. : HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol, 20: 13–24, 2012.

Janjigian Y.Y. , Werner D. , Pauligk C. , Steinmetz K. , Kelsen D.P. , Jäger E. , Altmannsberger H.M. , Robinson E. , Tafe L.J. , Tang L.H. , Shah M.A. , Al-Batran S.E. : Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol, 23: 2656–2662, 2012.

Bang Y.J. , Van Cutsem E. , Feyereislova A. , Chung H.C. , Shen L. , Sawaki A. , Lordick F. , Ohtsu A. , Omuro Y. , Satoh T. , Aprile G. , Kulikov E. , Hill J. , Lehle M. , Rüschoff J. , Kang Y.K. ; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376: 687–697, 2010.

Dai G.H. , Shi Y. , Chen L. , Lv Y.L. , Zhong M. : Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology, 59: 2439–2444, 2012.

Weissinger F. , Reymond M. , Dumke K. , Krüger M. : Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie, 34: 548–551, 2011.

Al-Batran S.E. , Ruppert M. , Jäger E. : Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report. Onkologie, 34: 42–45, 2011.

Al-Batran S.E. , Hartmann J.T. , Probst S. , Schmalenberg H. , Hollerbach S. , Hofheinz R. , Rethwisch V. , Seipelt G. , Homann N. , Wilhelm G. , Schuch G. , Stoehlmacher J. , Derigs H.G. , Hegewisch-Becker S. , Grossmann J. , Pauligk C. , Atmaca A. , Bokemeyer C. , Knuth A. , Jäger E. ; Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26: 1435–1442, 2008.

Al-Batran S.E. , Hartmann J.T. , Hofheinz R. , Homann N. , Rethwisch V. , Probst S. , Stoehlmacher J. , Clemens M.R. , Mahlberg R. , Fritz M. , Seipelt G. , Sievert M. , Pauligk C. , Atmaca A. , Jäger E. : Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 19: 1882–1887, 2008.

Kang Y.K. , Kang W.K. , Shin D.B. , Chen J. , Xiong J. , Wang J. , Lichinitser M. , Guan Z. , Khasanov R. , Zheng L. , Philco-Salas M. , Suarez T. , Santamaria J. , Forster G. , McCloud P.I. : Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20: 666–673, 2009.

Lee J.L. , Ryu M.H. , Chang H.M. , Kim T.W. , Yook J.H. , Oh S.T. , Kim B.S. , Lee J.S. , Kang Y.K. : Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Cancer Res Treat, 37: 201–207, 2005.

Dong N. , Jiang W. , Li H. , Liu Z. , Xu X. , Wang M. : Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol, 32: 559–563, 2009.

Hong Y.S. , Song S.Y. , Lee S.I. , Chung H.C. , Choi S.H. , Noh S.H. , Park J.N. , Han J.Y. , Kang J.H. , Lee K.S. , Cho J.Y. : A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol, 15: 1344–1347, 2004.

Al-Batran S.E. , Hozaeel W. , Jäger E. : Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. Onkologie, 35: 505–508, 2012.

Hegewisch-Becker S. , Moorahrend E. , Kröning H. , Petersen V. , Hannig C. , Pott D. , Tirier C. , Lerchenmuller C.A. , Schlag R. , Schneider-Kappus W. , Kaechele V. , Al-Batran S.E. : Trastuzumab (TRA) in combination with different firstline chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): findings from the German noninterventional observational study HerMES. J Clin Oncol, 30(suppl; abstr 4065): 2012.